Bringing together clinicians, researchers, families, and industry to develop new therapies for STXBP1-related disorders.
ESCO is an investigator-driven consortium of currently 7 European countries and Israel focused on promoting trial readiness for the treatment of STXBP1-related disorders. ESCO brings together all the relevant stakeholders in the space, including industrial partners and family associations, to foster collaborations that accelerate the creation of life-changing solutions for this patient population in need.
Information about STXBP1
STXBP1-related disorders are characterized by developmental delay and intellectual disability, most of the time associated with epilepsy, movement disorders, autism and other behavioral problems. Find more information on the disorder and the research towards STXBP1 and STXBP1-related disorders through the following links.